VASCULAR TUBULAR HUMAN BLOOD BRAIN BARRIER DEVICE
20190161717 ยท 2019-05-30
Inventors
Cpc classification
C12M35/08
CHEMISTRY; METALLURGY
C12M21/08
CHEMISTRY; METALLURGY
C12Q1/025
CHEMISTRY; METALLURGY
A61M1/00
HUMAN NECESSITIES
International classification
Abstract
The present disclosure provides an in vitro tubular blood brain barrier mimic used to model drug transport across the brain capillary endothelial barrier cells to neurons. In one embodiment the stack is comprised of interior neuro endothelial capillary cells, extracellular matrix, porous polymeric hollow fiber, exterior extracellular matrix, and neuron astrocytes. The tubular human blood brain barrier mimic is used to test molecular transport and effects of drug candidates across the multilayer stack.
Claims
1. A tubular in vitro blood brain barrier device, comprising: a tubular chamber having an interior surface; a first layer comprising a plurality of mammalian neurons in contact with a second layer having one or more agents that are biocompatible and are optionally adhered to at least some of the plurality of neurons, wherein the first layer is separated from the interior surface of the tubular chamber by a volume; a third layer comprising a tubular hollow fiber having pores, an interior surface and an exterior surface, which exterior surface of the third layer is in contact with the second layer; and a fourth layer having a plurality of endothelial cells in contact with a fifth layer having one or more agents that are biocompatible and are optionally adhered to at least some of the plurality of endothelial cells, which fifth layer is in contact with the interior surface of the hollow fiber, wherein the fourth layer forms a tube having a lumen having an annular volume.
2. The device of claim I wherein the second layer comprises gelatin, collagen, hyaluronic acid, cellulose, chemically modified cellulose, silicone, chitosan, vegetable protein, agar, polyacrylamide, polyvin.ylalcohol, polyols, fibronectin, vitronectin, laminin, matrigel, polylysine, polyvinylprylidone, or other polypeptides, or any combination thereof; or wherein the fifth layer comprises gelatin. collagen, hyaluronic acid, cellulose, chemically modified cellulose, silicone, chitosan, vegetable protein, agar, polyacrylamide, polyvinylalcohol, polyols, fibronectin, vitronectin, laminin, matrigel, polylysine, polyvinylprylidone, or other polypeptides, or any combination thereof; or wherein the hollow fiber comprises polysulphone, polyvinylidene fluoride, fluoropolymers polyethylene, polypropylene, nylon, polyester, cellulose, cellulose acetate, cellulose nitrate, polyacrylonitrile, polylactide, or polycaprolactone, or any combination thereof.
3-4. (canceled)
5. The device of claim 1 wherein a wall of the hollow fiber has a thickness from about 1 to about 50 microns or has a thickness from about 5 to about 10 microns.
6. (canceled)
7. The device of claim 1 wherein an inner diameter of the hollow fiber ranges from about 10 microns to about 1 millimeter or wherein an inner diameter of the hollow fiber ranges from about 50 to about 150 microns.
8. (canceled)
9. The device of claim 1 wherein the pores of the hollow fiber have a molecular weight cutoff of about 100 to about 50,000 KDa or wherein the pore size of the hollow fiber size allows for passage of molecules of less than 5000 KDa.
10. (canceled)
11. The device of claim 1 wherein the mammalian neurons are astrocytes.
12. (canceled)
13. The device of claim 1 wherein the endothelial cells comprise capillary endothelial cells.
14. (canceled)
15. The device of claim 1 wherein the thickness of the second layer or the fifth layer is from about 10 nanometers to 250 microns.
16. The device of claim 1 wherein the fourth layer comprises a single layer of endothelial cells.
17. The device of claim 1 wherein the mammalian neurons are human astrocytes and the endothelial cells comprise human brain capillary endothelial cells.
18. The device of claim 1 wherein the second layer or the fifth layer comprises hyaluronic acid.
19. (canceled)
20. The device of claim 1 wherein the second layer or the fifth layer further comprises cell adhesion peptide or polypeptide comprising RED, REDV and KREDVY.
21-22. (canceled)
23. A method of using a barrier device, comprising: providing the device of claim 1, wherein the volume that separates the first layer from the interior surface of the tubular chamber comprises a first aqueous liquid and the annular volume comprises a second aqueous liquid, wherein the second aqueous liquid comprises one or more test compounds; and detecting whether the one or more tests compounds or a metabolite thereof are present in the first aqueous liquid or whether the one or more tests compounds alter the activity of the mammalian neurons.
24. The method of claim 23 wherein the one or more test compounds are introduced to the second aqueous liquid after the second aqueous liquid is introduced to the annular volume or wherein the one or more compounds alter the viability of the mammalian neurons or wherein the activity that is altered is action potential, impedance or conduction velocity.
25. The method of claim 23 wherein the first liquid and the second liquid before the one or more test compounds are provided to the second aqueous liquid, are different or wherein the second aqueous liquid is introduced under positive pressure which pressure is optionally physiological pressure.
26-29. (canceled)
30. A method of making a tubular in vitro blood brain barrier device, comprising: providing a tubular chamber having an interior surface, the lumen of which comprises a tubular hollow fiber having pores, an interior surface and an exterior surface; coating the exterior surface of the tubular hollow fiber with a second layer having one or more agents that are biocompatible and contacting the second layer with a plurality of neurons which adhere to the second layer, thereby forming a first layer, wherein the first layer is separated from the interior surface of the tubular chamber by a volume; and coating the interior surface of the tubular hollow fiber with a fifth layer having one or more agents that are biocompatible and contacting the fifth layer with a plurality of endothelial cells which adhere to the fifth layer, thereby forming a fourth layer, wherein the fifth layer has an interior diameter which has an annular volume.
31. The method of claim 30 wherein the plurality of neurons that are contacted with the second layer are in a culture medium or wherein the plurality of endothelial cells that are contacted with the fifth layer are in culture medium.
32-33. (canceled)
34. The method of claim 30 wherein the plurality of endothelial cells are contacted with the fifth layer before or after the plurality of neurons are contacted with the second layer.
35. (canceled)
36. The method of claim 30 wherein the plurality of endothelial cells are contacted with the fifth layer when the plurality of neurons are contacted with the second layer.
37. The method of claim 30 further comprising introducing a first aqueous liquid to the annular volume; or introducing a second aqueous liquid to the volume separating the interior surface of the tubular chamber and the first layer; or introducing a first aqueous liquid to the annular volume and introducing a second aqueous liquid to the volume separating the interior surface of the tubular chamber and the first layer.
38-39. (canceled)
Description
BRIEF DESCRIPTION OF DRAWINGS
[0017]
[0018]
[0019]
DETAILED DESCRIPTION
[0020] The following discussion is directed towards the various embodiments. Although one or more of these embodiments may be preferred, the embodiments disclosed should not be interpreted, or otherwise used, as a limiting the scope of the disclosure, including the claims. In addition one skilled in the art will understand that the following description has broad application, and the discussion of any embodiment is meant only to be exemplary of that embodiment, and not intended to intimate that the scope of the disclosure, including the claims, is limited to that embodiment.
[0021] As discussed above, there are challenges in having an in vitro model that can emulate a vascular BBB for the screening of potential therapeutic compounds such as small molecules and biomolecules for various brain related diseases.
[0022] In one embodiment, a tubular in vitro blood brain barrier device is provided. The device includes a tubular chamber having an interior surface; a first layer comprising a plurality of mammalian neurons disposed on a second layer having one or more agents that are biocompatible and are adhered to at least some of the plurality of neurons, wherein the first layer is separated from the interior surface of the tubular chamber by a volume; a third layer comprising a tubular hollow fiber having pores, an interior surface and an exterior surface, which exterior surface of the third layer is disposed on the second layer; and a fourth layer having a plurality of endothelial cells disposed on a fifth layer having one or more agents that are biocompatible and are adhered to at least some of the plurality of endothelial cells, which fifth layer is disposed on the interior surface of the hollow fiber, wherein the fourth layer forms a tube having a lumen having an annular volume. In one embodiment, the second layer comprises gelatin, collagen, hyaluronic acid, cellulose, chemically modified cellulose, silicone, chitosan, vegetable protein, agar, polyacrylamide, polyvinylalcohol, polyols, fibronectin, vitronectin, laminin, matrigel, polylysine, polyvinylpyrrolidone, or other polypeptides, or any combination thereof. In one embodiment, the fifth layer comprises gelatin, collagen, hyaluronic acid, cellulose, chemically modified cellulose, silicone, chitosan, vegetable protein, agar, polyacrylamide, polyvinylalcohol, polyols, fibronectin, vitronectin, laminin, matrigel, polylysine, polyvinylprylidone, or other polypeptides, or any combination thereof. In one embodiment, the hollow fiber comprises polysulphone, polyvinylidene fluoride, fluoropolymers, polyethylene, polypropylene, nylon, polyester, cellulose, cellulose acetate, cellulose nitrate, polyacrylonitrile, polylactide, or polycaprolactone, or any combination thereof. In one embodiment, a wall of the hollow fiber has a thickness from about 1 to 50 microns. In one embodiment, a wall of the hollow fiber has a thickness from about 5 to 10 microns. In one embodiment, an inner diameter of the hollow fiber ranges from 10 microns to 1 millimeter. In one embodiment, an inner diameter of the hollow fiber ranges from 50 to 150 microns. In one embodiment, the pores of the hollow fiber have a molecular weight cutoff of 100 to 50,000 KDa. In one embodiment, the pore size of the hollow fiber size allows for passage of molecules of less than 5000 KDa but not greater than 5000 KDa. In one embodiment, the mammalian neurons are astrocytes, e.g., human astrocytes. In one embodiment, the endothelial cells comprise human brain capillary endothelial cells. In one embodiment, the thickness of the second layer or the fifth layer is from about 10 nanometers to 250 microns. In one embodiment, the fourth layer comprises a single layer of endothelial cells.
[0023] Referring to
[0024] Referring to
[0025]
[0026] In one embodiment, the cells used for the brain capillary endothelial cell (BCEC) 50 layer include cells from the hCMEC/D3 BBB cell line, which was derived from human temporal lobe microvessels; were immortalized with hTERT and SV40 large T antigen; and have been extensively characterized for brain endothelial phenotype and are a model of human blood-brain barrier (BBB) function. The cell line may be purchased from EMD Millipore Corporation in Temecula, Calif. This BCEC layer 50 may be used to study pathological and drug transport mechanisms with relevance to the central nervous system. The cells may be loaded into the hollow fibers via pumping and generally between 5 and 500,000,000 million cells are loaded into a hollow fiber device with multiple hollow fibers. The cells are loaded and allowed to expand to cover the entire hollow fiber wall and form tight junctions between the cells. During the cell loading the hollow fiber device may be rotated 360 degrees for over about a 24-hour period to assist in uniform cell converge and distribution on the hollow fiber walls 10.
[0027]
[0028] The hollow fiber device may then be allowed to age from 7 to 60 days to allow the cells to mature and form tight junction connections to each other and form a solid layer of cells on the both interior and exterior of the hollow fibers 10. During this time the neuro capillary cells are nourished, e.g., with EndoGro which is available from EMD Millipore of Concord Mass., and the astrocytes are also nourished, e.g., by BrainPhys which is available from StemCell Technologies, Vancouver Canada. The cells and device are then incubated at a temperature of 37 C. in a 95/5% oxygen to carbon dioxide atmosphere. In one embodiment, the cells are matured. Then the interior of the device may be charged with a molecule of interest
[0029] Referring to
[0030] The above discussion is meant to be illustrative of the principle and various embodiments. Numerous variations and modifications will become apparent to those skilled in the art once the above disclosure is fully appreciated. It is intended that the following claims be interpreted to embrace all such variations and modifications.